Project Grant R37CA294177
Award Date
9/5/24
Completion Date
8/31/29
Dollars Obligated
$714K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Ann Arbor, MI 48109, USA
Similar Awards
This National Cancer Institute Federal Grant Award under the Cancer Research Manpower (CFDA 93.398) program provides $279,039 to the University of Maryland, Baltimore (UMB) to establish health state utilities across several treatments for low-risk, sub-centimeter thyroid cancer (papillary thyroid microcarcinoma). The 4-year project will estimate the utilities of active surveillance, partial thyroidectomy, and other treatment options using a preference-based instrument. These utilities will...
The National Cancer Institute (NCI) awarded a $386,866 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the Regents of the University of Michigan to develop individualized estimates of treatment benefit from hormone therapy for men with prostate cancer. The project aims to integrate models for other-cause mortality risk, distant metastases, and prostate cancer-specific mortality to provide personalized estimates of treatment outcomes, and to develop a web...
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides funding of $591,691.00 to the Regents of the University of Michigan to conduct a pragmatic randomized controlled trial evaluating the effectiveness of an intervention, called "Current Together After Cancer" (CTAC), to promote guideline-concordant colorectal cancer surveillance among survivors of stages II and III colorectal cancer. The key products and...
This Project Grant award of $171,135 from the National Cancer Institute (NCI), under its Cancer Research Manpower (CFDA 93.398) program, supports the development of a multi-level intervention to improve access to curative treatment for patients with small hepatocellular carcinoma (HCC), a type of liver cancer. The key objectives of this 5-year award are to: 1) identify barriers and facilitators to timely HCC treatment through qualitative research; 2) iteratively develop a multi-level...
This federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $593,383 to The Methodist Hospital Research Institute (HMRI) in Houston, TX to develop an AI-augmented, multimodal, label-free nonlinear optical microscopy system for rapid and precise diagnosis of thyroid cancer and lymph node metastasis. The key products and services being delivered under this 5-year project include: An AI-enhanced benchtop system capable of...
This Project Grant, awarded by the National Cancer Institute (NCI) under the federal Cancer Cause and Prevention Research program (CFDA 93.393), will support the development and evaluation of a tailored mobile intervention, the "PERCS-YA" tool, to reduce worry and distress among young adult cancer survivors. The $290,052 award to the Regents of the University of Michigan will fund stakeholder engagement, intervention refinement, and a Phase II efficacy trial utilizing...
This $2,282,687 federal Project Grant award was made by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393). The grant supports a multi-year research program to understand how different forms of care integration (structural, functional, normative, interpersonal, and process) in oncology practices are associated with quality of care and patient outcomes, including for marginalized populations. The research program involves four interrelated...
This is a Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Cause and Prevention Research program (CFDA 93.393), totaling $1,239,420.00 and commencing on September 4, 2024. The award will fund a longitudinal observational study to assess changes in interoception (the brain's processing of internal bodily sensations) along the cancer chemotherapy continuum and its relationship to chemotherapy-induced peripheral neuropathy (CIPN) in 120 patients with breast...
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides funding to The Medical College of Wisconsin, Inc. to implement an intervention targeting high-risk breast cancer patients who have poor adherence to oral endocrine therapy. The $678,927 award, effective August 6, 2024 through July 31, 2029, will support a randomized study to assess the impact of routine symptom monitoring and management with clinical pharmacist-led follow-up on patient...
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) will fund a research project titled "Interventions to Decrease Cancer Information Avoidance." The total funding amount is $637,596 over the award period from April 4, 2025 to March 31, 2030. The project aims to develop and test a video-based intervention strategy designed to reduce defensive avoidance of colorectal cancer information and increase engagement with...